The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Medibank (MPL) CEO Craig Drummond is stepping down from his role on June 30, marking the end of five years with the company
  • Before he departs, Drummond says the company will continue its focus on preventative healthcare, short stay programs, clinical homecare and access to virtual care
  • Medibank Chairman Mike Wilkins has praised Drummond for his tenure saying he’s leaving the company in a stronger position
  • Medibank Private shares are trading 3.36 per cent lower at $2.79

Medibank (MPL) CEO Craig Drummond is stepping down from his role on June 30, marking the end of five years with the company.

Before his departure, Drummond says the company will continue to focus on working to deliver more preventative healthcare, short stay programs, clinical homecare and access to virtual care, such as telehealth.

”Pleasingly, Medibank is on a clear strategic path to grow the private health insurance business at a faster rate and continue the transformation into a broader healthcare company,” Drummond said.

“’I could not have been blessed with a more competent executive leadership team or supportive board,” he continued.

Medibank Chairman Mike Wilkins praised Drummond for his contribution.

“Craig has done a wonderful job in leading and transforming Medibank. He will leave the company in a much stronger position, on a clear strategic path, with a great team. This is the mark of outstanding leadership,” Mike said.

Investors appear to be wary about the management shake-up, with Medibank shares closing  3.36 per cent lower at $2.79.

MPL by the numbers
More From The Market Online
Disability NDIS concept

Freedom Care Group reveals NDIS wants to ban it providing program services

Shares in Freedom Care Group (ASX:FCG) were down more than -3% on Wednesday after revealing the…
Image representing bacterial infections in the immune system

Recce reaches key dosing milestone in testing of skin infection gel

Recce Pharmaceuticals Ltd has successfully dosed 20 out of 30 participants in its Phase II trial…
Bank of England London town

Wellnex bumps first $3M payment for Pain Away into 1Q25 – when it lists in London

Wellnex Life Ltd (ASX:WNX) has unveiled its plans to defer a $2.95M payment to 360 Health…
DNA RNA therapy concept

PYC Therapeutics moves into final stage of child blindness study

PYC has been approved to escalate doses of its drug candidate VP-001, treating Retinitis Pigmentosa 11,…